How mavacamten inhibits myosin to alleviate inherited heart disease revealed using cryoEM @snmcmillan.bsky.social and qXL-MS @jaimedoesxlms.bsky.social brilliant collaborative effort!!
www.science.org/doi/10.1126/...
www.science.org/doi/10.1126/...
Mavacamten inhibits myosin activity by stabilizing the myosin interacting-heads motif and stalling motor force generation
Mechanism of the myosin inhibitor mavacamten is revealed by cryo-EM and cross-linking studies.
www.science.org
April 30, 2026 at 8:14 AM
How mavacamten inhibits myosin to alleviate inherited heart disease revealed using cryoEM @snmcmillan.bsky.social and qXL-MS @jaimedoesxlms.bsky.social brilliant collaborative effort!!
www.science.org/doi/10.1126/...
www.science.org/doi/10.1126/...
FDA Expands Mavacamten Indication to Pediatric Obstructive HCM Patients
FDA Expands Mavacamten Indication to Pediatric Obstructive HCM Patients
FDA Expands Mavacamten Indication to Pediatric Obstructive HCM Patients
mosbey@crf.org
Thu, 10/01/2026 - 13:24
Caitlin E. Cox
www.tctmd.com
October 1, 2026 at 5:41 PM
FDA Expands Mavacamten Indication to Pediatric Obstructive HCM Patients
"Mavacamten in Adolescents with Obstructive Hypertrophic Cardiomyopathy"
Recently published findings on mavacamten in adolescents with obstructive hypertrophic cardiomyopathy is advancing knowledge that could personalize care & improve long-term outcomes for young patients with heart disease.
Recently published findings on mavacamten in adolescents with obstructive hypertrophic cardiomyopathy is advancing knowledge that could personalize care & improve long-term outcomes for young patients with heart disease.
September 29, 2026 at 5:15 PM
"Mavacamten in Adolescents with Obstructive Hypertrophic Cardiomyopathy"
Recently published findings on mavacamten in adolescents with obstructive hypertrophic cardiomyopathy is advancing knowledge that could personalize care & improve long-term outcomes for young patients with heart disease.
Recently published findings on mavacamten in adolescents with obstructive hypertrophic cardiomyopathy is advancing knowledge that could personalize care & improve long-term outcomes for young patients with heart disease.
🚨 LATE BREAKING 🚨 10 Original Articles simultaneously published in NEJM and presented at #ESCCongress
Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy (ODYSSEY-HCM Phase 3 trial) nej.md/4oSZx2m
@escardio.bsky.social
Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy (ODYSSEY-HCM Phase 3 trial) nej.md/4oSZx2m
@escardio.bsky.social
August 30, 2025 at 7:01 PM
🚨 LATE BREAKING 🚨 10 Original Articles simultaneously published in NEJM and presented at #ESCCongress
Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy (ODYSSEY-HCM Phase 3 trial) nej.md/4oSZx2m
@escardio.bsky.social
Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy (ODYSSEY-HCM Phase 3 trial) nej.md/4oSZx2m
@escardio.bsky.social
Which 1️⃣ of the following is the best recommendation?
A. Mavacamten w/ obstructive HCM
B. Mavacamten w/ nonobstructive HCM
C. Surgical myectomy w/ obstructive HCM
D. Disopyramide w/ obstructive HCM
E. None of the above
Read the case details & comment below! 👇
#CardioSky #MedSky #ACCEd
A. Mavacamten w/ obstructive HCM
B. Mavacamten w/ nonobstructive HCM
C. Surgical myectomy w/ obstructive HCM
D. Disopyramide w/ obstructive HCM
E. None of the above
Read the case details & comment below! 👇
#CardioSky #MedSky #ACCEd
December 12, 2024 at 3:58 PM
Which 1️⃣ of the following is the best recommendation?
A. Mavacamten w/ obstructive HCM
B. Mavacamten w/ nonobstructive HCM
C. Surgical myectomy w/ obstructive HCM
D. Disopyramide w/ obstructive HCM
E. None of the above
Read the case details & comment below! 👇
#CardioSky #MedSky #ACCEd
A. Mavacamten w/ obstructive HCM
B. Mavacamten w/ nonobstructive HCM
C. Surgical myectomy w/ obstructive HCM
D. Disopyramide w/ obstructive HCM
E. None of the above
Read the case details & comment below! 👇
#CardioSky #MedSky #ACCEd
Phenomenally proud that this work is out in the wild now - excellent feeling having my qXL-MS of myosin conformational dynamics paired with @snmcmillan.bsky.social incredible cryo-EM work and analysis. A real team effort from @scarfflab.bsky.social
www.science.org/doi/10.1126/...
www.science.org/doi/10.1126/...
Mavacamten inhibits myosin activity by stabilizing the myosin interacting-heads motif and stalling motor force generation
Mechanism of the myosin inhibitor mavacamten is revealed by cryo-EM and cross-linking studies.
www.science.org
April 29, 2026 at 9:35 PM
Phenomenally proud that this work is out in the wild now - excellent feeling having my qXL-MS of myosin conformational dynamics paired with @snmcmillan.bsky.social incredible cryo-EM work and analysis. A real team effort from @scarfflab.bsky.social
www.science.org/doi/10.1126/...
www.science.org/doi/10.1126/...
Mavacamten makes LGE go away!?
Effects of Mavacamten on Cardiac Magnetic Resonance Features in Chinese Patients With Obstructive Hypertrophic Cardiomyopathy | JACC: Asia www.jacc.org/doi/10.1016/...
Effects of Mavacamten on Cardiac Magnetic Resonance Features in Chinese Patients With Obstructive Hypertrophic Cardiomyopathy | JACC: Asia www.jacc.org/doi/10.1016/...
Effects of Mavacamten on Cardiac Magnetic Resonance Features in Chinese Patients With Obstructive Hypertrophic Cardiomyopathy:
www.jacc.org
July 13, 2025 at 1:03 PM
Mavacamten makes LGE go away!?
Effects of Mavacamten on Cardiac Magnetic Resonance Features in Chinese Patients With Obstructive Hypertrophic Cardiomyopathy | JACC: Asia www.jacc.org/doi/10.1016/...
Effects of Mavacamten on Cardiac Magnetic Resonance Features in Chinese Patients With Obstructive Hypertrophic Cardiomyopathy | JACC: Asia www.jacc.org/doi/10.1016/...
Mechanism of mavacamten inhibition of myosin - check out our preprint here: www.biorxiv.org/content/10.1...
Mavacamten inhibits myosin activity by stabilising the myosin interacting-heads motif and stalling motor force generation
Most sudden cardiac deaths in young people arise from hypertrophic cardiomyopathy, a genetic disease of the heart muscle, with many causative mutations found in the molecular motor beta-cardiac myosin...
www.biorxiv.org
February 17, 2025 at 8:03 PM
Mechanism of mavacamten inhibition of myosin - check out our preprint here: www.biorxiv.org/content/10.1...
ODYSSEY-HCM phase 3 trial: Mavacamten is approved to treat patients with symptomatic obstructive hypertrophic cardiomyopathy, but its clinical effects in nonobstructive hypertrophic cardiomyopathy are unclear. Research findings are summarized in a new Quick Take video. nej.md/47TMwQb
#MedSky
#MedSky
September 14, 2025 at 7:00 PM
ODYSSEY-HCM phase 3 trial: Mavacamten is approved to treat patients with symptomatic obstructive hypertrophic cardiomyopathy, but its clinical effects in nonobstructive hypertrophic cardiomyopathy are unclear. Research findings are summarized in a new Quick Take video. nej.md/47TMwQb
#MedSky
#MedSky
December 12, 2024 at 2:12 PM
Mavacamten shows broad benefit in human and mouse models of MYBPC3 -related hypertrophic cardiomyopathy
->Nature | More on "Mavacamten treating hypertrophic cardiomyopathy research" at BigEarthData.ai
->Nature | More on "Mavacamten treating hypertrophic cardiomyopathy research" at BigEarthData.ai
Mavacamten shows broad benefit in human and mouse models of MYBPC3 -related hypertrophic cardiomyopathy
Marian, A. J. & Braunwald, E. Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. Circ. Res. 121, 749–770 (2017). Goyal, N. et al. Hypertrophic cardiomyopathy – phenotypic variations beyond wall thickness. Clin. Imaging 95, 80–89 (2023). Nag, S., Gollapudi, S. K., Del Rio, C. L., Spudich, J. A. & McDowell, R. Mavacamten, a precision medicine for hypertrophic cardiomyopathy: from a motor protein to patients. Sci. Adv. 9, eabo7622 (2023). Suay-Corredera, C. & Alegre-Cebollada, J. The mechanics of the heart: zooming in on hypertrophic cardiomyopathy and cMyBP-C. FEBS Lett. 596, 703–746 (2022). Marian, A. J. Molecular genetic basis of hypertrophic cardiomyopathy. Circ. Res. 128, 1533–1553 (2021). Hessel, A. L. et al. Myosin-binding protein C regulates the sarcomere lattice and stabilizes the OFF states of myosin heads. Nat. Commun. 15, 2628 (2024). Schmid, M. & Toepfer, C. N. Cardiac myosin super relaxation (SRX): a perspective on fundamental biology, human disease and therapeutics. Biol. Open 10, bio057646 (2021). Adhikari, A. S. et al. beta-Cardiac myosin hypertrophic cardiomyopathy mutations release sequestered heads and increase enzymatic activity. Nat. Commun. 10, 2685 (2019). Sarkar, S. S. et al. The hypertrophic cardiomyopathy mutations R403Q and R663H increase the number of myosin heads available to interact with...
www.nature.com
July 8, 2026 at 3:45 AM
Mavacamten has been approved for adults with hypertrophic cardiomyopathy since 2022, but hadn’t yet been tested in adolescents or children.
Once-daily pill could help teens with common genetic heart disease, CHOP-led study finds
www.inquirer.com
March 29, 2026 at 4:58 PM
Mavacamten has been approved for adults with hypertrophic cardiomyopathy since 2022, but hadn’t yet been tested in adolescents or children.
Esperti: 'Mavacamten è il primo inibitore della miosina cardiaca approvato per il trattamento della Cmio, ha introdotto un approccio innovativo'
Cardiomiopatia ipertrofica ostruttiva: "Terapia innovativa efficace e sicura a 5 anni"
ebx.sh
October 1, 2026 at 1:53 AM
Esperti: 'Mavacamten è il primo inibitore della miosina cardiaca approvato per il trattamento della Cmio, ha introdotto un approccio innovativo'
Bristol Myers Squibb said that mavacamten (Camzyos)failed to meet functional and symptom improvement endpoints in the ODYSSEY-HCM trial of non-obstructive hypertrophic cardiomyopathy.
news.bms.com/news/details...
#CardioSky #Cardiology #Cardiomyopathy #HCM
news.bms.com/news/details...
#CardioSky #Cardiology #Cardiomyopathy #HCM
Bristol Myers Squibb Provides Update on Phase 3 ODYSSEY-HCM Trial
Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 ODYSSEY-HCM trial evaluating Camzyos (mavacamten) for the treatment of adult patients with symptomatic New York Heart Association (NYHA) cl...
news.bms.com
April 16, 2025 at 4:51 AM
Bristol Myers Squibb said that mavacamten (Camzyos)failed to meet functional and symptom improvement endpoints in the ODYSSEY-HCM trial of non-obstructive hypertrophic cardiomyopathy.
news.bms.com/news/details...
#CardioSky #Cardiology #Cardiomyopathy #HCM
news.bms.com/news/details...
#CardioSky #Cardiology #Cardiomyopathy #HCM
In patients with nonobstructive HCM, mavacamten did not significantly improve peak oxygen uptake or decrease symptoms as compared with placebo, and more patients had a reduction in LVEF with mavacamten. Full ODYSSEY-HCM phase 3 trial results and Research Summary: nej.md/4oSZx2m
#MedSky
#MedSky
September 16, 2025 at 1:04 PM
In patients with nonobstructive HCM, mavacamten did not significantly improve peak oxygen uptake or decrease symptoms as compared with placebo, and more patients had a reduction in LVEF with mavacamten. Full ODYSSEY-HCM phase 3 trial results and Research Summary: nej.md/4oSZx2m
#MedSky
#MedSky
Shkreli got rich by manipulating the price of Daraprim, another very expensive drug that is completely unrelated to Revlimid
However … and I am absolutely not making this up… Shkreli’s personal web site includes financial models for many different drugs, including Revlimid
However … and I am absolutely not making this up… Shkreli’s personal web site includes financial models for many different drugs, including Revlimid
May 11, 2025 at 7:27 PM
Shkreli got rich by manipulating the price of Daraprim, another very expensive drug that is completely unrelated to Revlimid
However … and I am absolutely not making this up… Shkreli’s personal web site includes financial models for many different drugs, including Revlimid
However … and I am absolutely not making this up… Shkreli’s personal web site includes financial models for many different drugs, including Revlimid
Mavacamten facilitates myosin head ON-to-OFF transitions and shortens thin filament length in relaxed skeletal muscle https://www.biorxiv.org/content/10.1101/2024.11.29.626031v1
Mavacamten facilitates myosin head ON-to-OFF transitions and shortens thin filament length in relaxed skeletal muscle https://www.biorxiv.org/content/10.1101/2024.11.29.626031v1
The first-in-its-class cardiac drug mavacamten reduces the proportion of so-called ON-state myosin h
www.biorxiv.org
December 3, 2024 at 10:02 PM
Mavacamten facilitates myosin head ON-to-OFF transitions and shortens thin filament length in relaxed skeletal muscle https://www.biorxiv.org/content/10.1101/2024.11.29.626031v1
New in the September 11, 2025, issue of NEJM:
Aficamten or Metoprolol for Hypertrophic Cardiomyopathy (MAPLE-HCM phase 3 trial) nej.md/45zDWo3
Mavacamten in Nonobstructive Hypertrophic Cardiomyopathy (ODYSSEY-HCM phase 3 trial) nej.md/4oSZx2m
#MedSky
Aficamten or Metoprolol for Hypertrophic Cardiomyopathy (MAPLE-HCM phase 3 trial) nej.md/45zDWo3
Mavacamten in Nonobstructive Hypertrophic Cardiomyopathy (ODYSSEY-HCM phase 3 trial) nej.md/4oSZx2m
#MedSky
September 11, 2025 at 2:05 PM
New in the September 11, 2025, issue of NEJM:
Aficamten or Metoprolol for Hypertrophic Cardiomyopathy (MAPLE-HCM phase 3 trial) nej.md/45zDWo3
Mavacamten in Nonobstructive Hypertrophic Cardiomyopathy (ODYSSEY-HCM phase 3 trial) nej.md/4oSZx2m
#MedSky
Aficamten or Metoprolol for Hypertrophic Cardiomyopathy (MAPLE-HCM phase 3 trial) nej.md/45zDWo3
Mavacamten in Nonobstructive Hypertrophic Cardiomyopathy (ODYSSEY-HCM phase 3 trial) nej.md/4oSZx2m
#MedSky
@michelkuehn.bsky.social has his first paper under review! Mavacamten is a cardiac drug that "deactivates" myosin heads, which structurally shows as the heads moved away from the thin filament, even in relaxed muscle and is now shown in skeletal muscle! 👨🔬🔬🧪 #MyoBlue
www.biorxiv.org/content/10.1...
www.biorxiv.org/content/10.1...
December 4, 2024 at 10:11 AM
@michelkuehn.bsky.social has his first paper under review! Mavacamten is a cardiac drug that "deactivates" myosin heads, which structurally shows as the heads moved away from the thin filament, even in relaxed muscle and is now shown in skeletal muscle! 👨🔬🔬🧪 #MyoBlue
www.biorxiv.org/content/10.1...
www.biorxiv.org/content/10.1...
Much needed, and reassuring, real-world data on the patient experience with mavacamten @CircHF
January 23, 2025 at 12:22 AM
Much needed, and reassuring, real-world data on the patient experience with mavacamten @CircHF
Great real-world data on Mavacamten that helps understand the risk for heart failure induced by the drug:
4% of the 6000+ patients studied - 1% required hospitalization.
#cardiosky
4% of the 6000+ patients studied - 1% required hospitalization.
#cardiosky
January 23, 2025 at 8:18 AM
Great real-world data on Mavacamten that helps understand the risk for heart failure induced by the drug:
4% of the 6000+ patients studied - 1% required hospitalization.
#cardiosky
4% of the 6000+ patients studied - 1% required hospitalization.
#cardiosky
Mavacamten significantly reduced left ventricular outflow tract obstruction and improved symptoms in adolescents with obstructive hypertrophic cardiomyopathy compared to placebo. doi.org/hbvcf3
Mavacamten improves obstruction in adolescents with hypertrophic cardiomyopathy
Adolescent patients with obstructive hypertrophic cardiomyopathy (HCM) who received the drug mavacamten saw a significant improvement in left ventricular outflow tract (LVOT) gradient, a measure of blood flow obstruction in the heart, compared with those who received a placebo, according to a small study presented at the American College of Cardiology's Annual Scientific Session (ACC.26).
medicalxpress.com
March 30, 2026 at 11:00 PM
Mavacamten significantly reduced left ventricular outflow tract obstruction and improved symptoms in adolescents with obstructive hypertrophic cardiomyopathy compared to placebo. doi.org/hbvcf3
🧪 Wondering whether mavacamten would provide therapeutic benefit for #noonansyndrome #HCM? 👇
🫀Therapeutic Response to Myosin Inhibitor Therapy in Noonan Syndrome–Associated Obstructive Hypertrophic Cardiomyopathy | JACC: Case Reports
#medsky #cardiosky
www.jacc.org/doi/10.1016/...
🫀Therapeutic Response to Myosin Inhibitor Therapy in Noonan Syndrome–Associated Obstructive Hypertrophic Cardiomyopathy | JACC: Case Reports
#medsky #cardiosky
www.jacc.org/doi/10.1016/...
Therapeutic Response to Myosin Inhibitor Therapy in Noonan Syndrome–Associated Obstructive Hypertrophic Cardiomyopathy:
www.jacc.org
December 6, 2025 at 3:22 PM
🧪 Wondering whether mavacamten would provide therapeutic benefit for #noonansyndrome #HCM? 👇
🫀Therapeutic Response to Myosin Inhibitor Therapy in Noonan Syndrome–Associated Obstructive Hypertrophic Cardiomyopathy | JACC: Case Reports
#medsky #cardiosky
www.jacc.org/doi/10.1016/...
🫀Therapeutic Response to Myosin Inhibitor Therapy in Noonan Syndrome–Associated Obstructive Hypertrophic Cardiomyopathy | JACC: Case Reports
#medsky #cardiosky
www.jacc.org/doi/10.1016/...
Check out the July 2026 #SBEpaperofthemonth
Sen-Martín et al, "Mavacamten shows broad benefit in human and mouse models of MYBPC3-related hypertrophic cardiomyopathy"
@natcardiovascres.nature.com 2026 Jul;5(7):638-657. doi: 10.1038/s44161-026-00833-3
Sen-Martín et al, "Mavacamten shows broad benefit in human and mouse models of MYBPC3-related hypertrophic cardiomyopathy"
@natcardiovascres.nature.com 2026 Jul;5(7):638-657. doi: 10.1038/s44161-026-00833-3
August 28, 2026 at 10:44 AM
Check out the July 2026 #SBEpaperofthemonth
Sen-Martín et al, "Mavacamten shows broad benefit in human and mouse models of MYBPC3-related hypertrophic cardiomyopathy"
@natcardiovascres.nature.com 2026 Jul;5(7):638-657. doi: 10.1038/s44161-026-00833-3
Sen-Martín et al, "Mavacamten shows broad benefit in human and mouse models of MYBPC3-related hypertrophic cardiomyopathy"
@natcardiovascres.nature.com 2026 Jul;5(7):638-657. doi: 10.1038/s44161-026-00833-3